Clinical Trials
3 trialsNCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT02953652 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
Phase 2 Completed
NCT02955589 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
HUYABIO International, LLC.
Phase 2 Completed